Rhythm

GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

WESTMINSTER, Colo., Nov. 12, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial were presented November 11, 2018 in a poster session at […]

AliveCor’s Mobile ECG Technology Could Enable More Rapid Diagnosis and Treatment of Heart Attacks

MOUNTAIN VIEW, Calif., Nov. 12, 2018 /PRNewswire/ — AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, has announced that a research version of its mobile technology can identify ST-elevation myocardial infarction (STEMI), the most severe form of heart attack. The findings of the ST LEUIS International Multicenter Study, to be announced at […]

Cardiva Medical Announces Positive Results of the AMBULATE Pivotal Study Evaluating the VASCADE MVP System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures

SANTA CLARA, Calif. & CHICAGO–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that VASCADE® MVP, the first vascular closure system designed specifically for multi-access venous closure following electrophysiology procedures such as arrhythmia ablation, met its endpoints compared to manual compression in a pivotal clinical […]

InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones

SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today provided a corporate update highlighting fundraising and clinical development milestones.  These achievements have contributed to the continued successful development of its lead clinical program, while […]

Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)

NEW HOPE, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that Professor Petr Neuzil, M.D., Head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech […]

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 Scientific Sessions of the American Heart Association (AHA)

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing, is proud to announce its participation as an exhibitor at the upcoming 2018 Scientific Sessions of the American Heart Association (AHA). The AHA Congress will take place November 10-12, 2018 at […]

Medical Device Startup HeartHero Announces Agreement With Vivaquant

DENVER, Nov. 6, 2018 /PRNewswire/ — Medical device startup, HeartHero has signed an agreement to license VivaQuant MDSP cardiac arrhythmia detection technology for its portable AED. HeartHero will leverage VivaQuant’s ground breaking arrhythmia technology to detect fatal heart rhythms and provide crucial lifesaving technology. In September, HeartHero won the ACEP InnovatED competition for most innovative medical device […]

ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions

WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) —  ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial have been selected for a poster presentation […]

Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

COPENHAGEN, Denmark, November 5, 2018 /PRNewswire/ — – Phase 1 data show favourable safety profile – Data support further development of AP30663 for cardioversion therapy Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its […]

Cardiac Insight, Inc. Partners with VivoSense® (Vivonoetics, Inc.) to Expand the Use of Its Wearable Cardiac Sensors in Regulated Pharmaceutical Clinical Trials and Other Healthcare Research Applications

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, announced today it has partnered with VivoSense®, a leader in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will […]